EPO and retinal disorder: All patients completing this study will be eligible for entry into a 2-year, open-label extension to enable monitoring of emergent adverse events, anti-erythropoietin antibody responses, maintenance of efficacy and changes in retinopathy status among the diabetic subpopulation.